<DOC>
	<DOCNO>NCT01196260</DOCNO>
	<brief_summary>This study examine new combination drug : Capecitabine Oxaliplatin treatment Stage II III colorectal cancer . Capecitabine Oxaliplatin approve Food Drug Administration ( FDA ) use colorectal cancer . The combination drug experimental ( approved FDA standard treatment ) , widely use treatment option preliminary study show treatment combination positive effect metastatic colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Treatments Patients With Colorectal Cancer Stage II III</brief_title>
	<detailed_description>This study examine new combination drug : Capecitabine Oxaliplatinfor treatment Stage II III colorectal cancer . Capecitabine Oxaliplatin approve Food Drug Administration ( FDA ) use colorectal cancer . The combination drug experimental ( approved FDA standard treatment ) , widely use treatment option preliminary study show treatment combination positive effect metastatic colorectal cancer . In present trial , study combination two drug patient colorectal cancer among Chinese population</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Patient must histologically prove TNM stage II III adenocarcinoma colon rectum . Patient must receive curative surgical cancer free margin . Patients must performance status 0,1 , 2 . Patients must absolute neutrophil count great equal 1500/ml , platelet count great equal 100,000/ml , total serum bilirubin equal less institution 's upper limit normal range . Patients must fully recover effect surgery . Patients must provide sign consent participate study . Age : •18 Performance status : •WHO 02 Life expectancy : •Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST/ALT great 1.5 time ULN Renal : •Creatinine clearance great 30 mL/min Cardiovascular : More 12 month since prior active clinically significant cardiovascular disease , include follow : Cerebrovascular accident Myocardial infarction Unstable angina New York Heart Association class IIIV congestive heart failure Serious cardiac arrhythmia require medication Uncontrolled hypertension ( i.e. , blood pressure &gt; 150/100 mm Hg ) Other : Not pregnant nursing Fertile patient must use effective contraception No active peptic ulcer gastrointestinal bleeding within past year No inflammatory bowel disease No malignancy within past 10 year except adequately treat carcinoma situ cervix basal cell squamous cell skin cancer Patients proven history peptic ulcer disease gastroesophageal reflux . Patients experience asthma , urticaria , allergictype reaction take aspirin nonsteroidal antiinflammatory drug . Patients receive prior chemotherapy colorectal cancer except patient relapse 6 month completion adjuvant chemotherapy . History malignancy , except cancer treat curative intent patient without evidence active disease . Unresolved bacterial infection require treatment antibiotic . Pregnant lactate woman may participate study . Women/men reproductive age group may participate unless agree use effective method contraception . Patients allergy study drug . Patients know HIV1 virus infection undetermined effect chemotherapy regimen patient HIV1 potential serious interaction antiHIV medication . Gilbert 's disease . Lack physical integrity upper gastrointestinal tract . Inability swallow tablet malabsorption syndrome . Other serious concurrent infection Clinically significant cardiac disease well control medication ( e.g . congestive heart failure , symptomatic coronary artery disease cardiac arrhythmia ) myocardial infarction within last 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>efficiency</keyword>
	<keyword>capecitabine</keyword>
	<keyword>oxaliplatin</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>